Condition

EGF-R Positive Non-Small Cell Lung Cancer

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting2
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCNCT06109558 · 2023-12-31
RECRUITING
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesNCT05033691 · 2021-03-09
RECRUITING
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNCT06557096 · 2024-08-20
NOT_YET_RECRUITING
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLCNCT06287593 · 2024-04-15
NOT_YET_RECRUITING
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)NCT05998993 · 2023-11-01
NOT_YET_RECRUITING
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung CancerNCT05573373 · 2022-12-20
UNKNOWN
Endobronchial Ultrasound Needle Aspiration With and Without SuctionNCT05110950 · 2022-06-01
UNKNOWN
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290 · 2022-03-31
ACTIVE_NOT_RECRUITING
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain MetastasisNCT06352502 · 2022-01-28
UNKNOWN
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCNCT05153408 · 2022-01-13
TERMINATED
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNCT05132985 · 2022-01-01
NOT_YET_RECRUITING
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung CarcinomaNCT05165355 · 2021-12-28
UNKNOWN
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCNCT04989322 · 2021-10-05
UNKNOWN
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780 · 2021-06-29
TERMINATED
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNCT04464967 · 2021-03-01
WITHDRAWN
Dacomitinib in Lung Cancer With Uncommon EGFR MutationsNCT04504071 · 2020-12-08
ACTIVE_NOT_RECRUITING
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerNCT03749213 · 2018-12-01
UNKNOWN
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerNCT03349203 · 2018-10-01
UNKNOWN
First Line Osimertinib in the Real World: an Inter-regional Prospective StudyNCT04965701 · 2018-06-01
COMPLETED
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung CancerNCT06207292 · 2016-12-01
UNKNOWN
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With AfatinibNCT04640870 · 2015-03-15
COMPLETED

Common interventions

Leading sponsors

Trial status mix

UNKNOWN8
NOT_YET_RECRUITING4
ACTIVE_NOT_RECRUITING2
COMPLETED2
RECRUITING2
TERMINATED2
WITHDRAWN1

Phase mix

PHASE29
PHASE16
NA5
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.